Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase DeficiencyBusiness Wire • 07/13/20
Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant OsteopetrosisBusiness Wire • 06/29/20
Rocket Pharmaceuticals: Updating Our Bullish View For Recent Events - Still A BUYSeeking Alpha • 05/27/20
Here's Why Rocket Pharmaceuticals (RCKT) is a Great Momentum Stock to BuyZacks Investment Research • 01/06/20
Rocket Pharmaceuticals, Inc. (RCKT) Shares March Higher, Can It Continue?Zacks Investment Research • 12/04/19